^
Association details:
| Biomarker: | EGFR exon 20 insertion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Afatinib 30 mg in the treatment of common and uncommon EGFR-mutated advanced lung adenocarcinomas: a retrospective, single-center, longitudinal study
Published date:
06/09/2022
Excerpt:
EGFR-mutated advanced LAD patients receiving afatinib (30 mg/d) from January 2017 to November 2021 were retrospectively included....Patients with EGFR 20ins had a significantly poorer PFS compared to patients with other EGFR common and uncommon mutations (2.37 vs. 14.53 vs. 10.39 months, P<0.001) (Figure 1B). Similarly, patients with EGFR 20ins had a remarkably lower ORR (0% vs. 60% vs. 80%, P=0.023) and DCR (75% vs. 100% vs. 100%, P=0.039) compared to patients with common and uncommon EGFR mutations (Table 3).
DOI:
10.21037/jtd-22-507
